CN101181069B - Complex nutrition albumen powder for preventing women's osteosporosis after menopause - Google Patents
Complex nutrition albumen powder for preventing women's osteosporosis after menopause Download PDFInfo
- Publication number
- CN101181069B CN101181069B CN200710150586XA CN200710150586A CN101181069B CN 101181069 B CN101181069 B CN 101181069B CN 200710150586X A CN200710150586X A CN 200710150586XA CN 200710150586 A CN200710150586 A CN 200710150586A CN 101181069 B CN101181069 B CN 101181069B
- Authority
- CN
- China
- Prior art keywords
- percent
- isoflavones
- women
- albumen powder
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a compound protein powder for preventing postmenopausal women from osteoporosis. The components and weight percentage thereof are: 55 percent to 80 percent of soybean protein powder; 15 percent to 35 percent of whey powder, 0.2 percent to 0.8 percent of soybean isoflavone, 1 percent to 5 percent of oligosaccharide, 1.2 percent to 2.4 percent of calcium lactate, 0.5 percent to 1 percent of stabilizer and 0.5 percent to 1.5 percent of lecithin. The product of the invention is safe and reliable to eat, which has good effect, innocuity, no side effects and dependence. Furthermore, the invention can protect the health of middle-aged women by eating often, especially for improving the healthy problems caused by lacking of estrogen, so as to improve the life quality and living quality of women. Therefore, the invention can be taken as a protein complementary product to be eaten frequently by women.
Description
Technical field
The present invention relates to a kind of complex nutrition albumen powder, relate in particular to a kind of complex nutrition albumen powder that is used to prevent women's osteosporosis after menopause.
Background technology
Along with China aged's increase, osteoporosis also becomes the disease of another our health of threat after angiocardiopathy and cancer.Investigation shows that China has the maximum country of patients with osteoporosis in the world at present, and 9,000 ten thousand patients are arranged approximately, accounts for 7% of total population.
Osteoporosis is particularly serious to postmenopausal women's harm.Body inner estrogen level sharply descends behind the postmenopausal women, and the inhibition of osteoclast is weakened, and the bone dissolving is quickened, and bone formation effect dies down, and causes bone calcium to lose in a large number, thereby causes osteoporosis.In China, 60～69 years old elderly woman incidence of osteoporosis be up to 50%～70%, therefore, how to prevent PMO, what prevent to fracture is the important topic that we need pay close attention to.
Controversies in hormone replacement in the elderly (HRT) is the osteoporotic main method of prevention postmenopausal women; A large amount of research shows that using HRT can be good at the prevention of postmenopausal osteoporosis; But HRT can produce its side effect in prevention of osteoporosis; Like the bad reaction of breast cancer, oophoroma, cardiovascular disease and stomach and intestine etc., and some women's psychology misgivings, can not be accepted by all lack estrogenic women.
Along with further understanding and research to plant-derived estrogen-like product, pharmacy man begins interest has been taken place phytoestrogen.At present, phytoestrogen especially osajin propagated and be " health care product ".Isoflavones in soybean with estrogen action, the especially soybean has certain prevention effect to PMO.
Summary of the invention
The purpose of this invention is to provide a kind of can be comprehensively, effectively, the complex nutrition albumen powder of safety precautions women's osteosporosis after menopause, with the health of protection middle-aged women, improve quality of life and quality of life.
The technical scheme that the present invention takes is:
A kind of complex nutrition albumen powder that prevents women's osteosporosis after menopause, its constituent and percentage by weight thereof are respectively:
Soyabean protein powder 55～80%
PURE WHEY 15～35%
Isoflavones 0.2～0.8%
Compound sugar 1～5%
Calcium lactate 1.2～2.4%
Stabilizing agent 0.5～1%
Lecithin 0.5～1.5%.
And described soyabean protein powder is a soybean protein isolate, its protein content >=60%.
And described PURE WHEY is a WPC, its protein content >=60%.
And, total isoflavone content >=40% in the described isoflavones.
And the content of described isoflavones is to calculate with total isoflavone content.
And described compound sugar is soyabean oligosaccharides or oligoisomaltose or FOS or low poly lactose or galactooligosaccharide.
And described stabilizing agent is xanthans or carragheen, or both mixtures.
And described lecithin is the lecithin of homogeneous.
Advantage of the present invention and good effect are:
1. the present invention is the main body with soybean isolate protein powder and PURE WHEY; Utilize the animal/vegetable protein complementarity principle; Soybean protein and lactalbumin being mixed by a certain percentage, make its nine kinds of contents of essential amino acids more near the amino acid pattern of needed by human body, very easily is absorption of human body and utilization; In prescription, add emulsifier lecithin and stabilizing agent xanthans in addition or/and carragheen makes albumen powder have good stable property and organoleptic quality.
2. the present invention has strengthened function composition isoflavones and the compound sugar that promotes that isoflavones absorbs, thereby reaches the osteoporotic effect of prevention menopausal women.Prevention effect test to the removal ovary osteoporosis rat shows: the nutrition albumen powder of reinforcement isoflavones has prevention effect to the osteoporosis of removal ovary rat.
3. the compound sugar that the present invention added can be regulated the body gastrointestinal tract normal flora; Generation specific enzymes system; Can not only promote that endogenous estrogen absorbs again, improve the endogenous estrogen level of body, can also improve the absorption of isoflavones and absorption more simultaneously; Have the double action that improves endogenous estrogen level and supplemented with exogenous property estrogen-like product, thus for prevention PMO, climacteric syndrome and breast cancer have effect more significantly.
4. function composition isoflavones of the present invention can be alleviated the various discomforts of female climacteric syndrome, improves sleep; Can prevent cardiovascular and cerebrovascular disease, reduce the generation of women breast cancer, control senile dementia (Alzheimer disease) is also had certain effectiveness.
5. function composition compound sugar of the present invention also has reducing blood lipid, hypoglycemic, the effects such as absorption that promote mineral element.
6. the calcium lactate among the present invention is the calcium source, under the existence and effect of isoflavones, is absorbed by the body easily.
7. the anti-oxidant and emulsification of lecithin tool among the present invention more is prone to by human consumption and absorption albumen powder, and helps protein to mix, and is difficult for forming blob of viscose, dissolves faster and better.
8. product edible safety of the present invention is reliable, effective, has no side effect, and no dependence can be used as the often edible protein supplementary of women.
The specific embodiment
Below in conjunction with embodiment, the present invention is further specified; Following embodiment is illustrative, is not determinate, can not limit protection scope of the present invention with following embodiment.
At first need to prove:
Soyabean protein powder is a soybean protein isolate, its protein content >=60%.
PURE WHEY is a WPC, its protein content >=60%.
Total isoflavone content >=40% in the isoflavones, the content of this isoflavones calculates with total isoflavone content.
Compound sugar can adopt the wherein a kind of of soyabean oligosaccharides or oligoisomaltose or FOS or low poly lactose or galactooligosaccharide.
Embodiment 1: (following each raw material percentage composition is weight percentage)
Soyabean protein powder 75%
PURE WHEY 25%
Isoflavones 0.3%
Soyabean oligosaccharides 3%
Calcium lactate 2%
Xanthans 0.7%
Lecithin 1%.
Production craft step of the present invention is following:
Take by weighing soyabean protein powder, PURE WHEY, xanthans, calcium lactate, compound sugar and the lecithin mixing of homogeneous respectively by above-mentioned percetage by weight; Method according to the patent 2006100133037.3 of the applicant application " should have albumen powder that ebullated bed spraying lecithin granulating technique produces and preparation method thereof " and introduced is produced compound protein powder, collects, and adds isoflavones; Mixing; Sterilization, aseptic packaging, 25g packing, dress parcel, dress wrap greatly, case.Check, finished product warehouse-in.
Embodiment 2: (following each raw material percentage composition is weight percentage)
Soyabean protein powder 80%
PURE WHEY 20%
Isoflavones 0.5%
Oligoisomaltose 5%
Calcium lactate 2%
Carragheen 0.7%
Lecithin 1%.
Preparation technology's step is with embodiment 1.
Embodiment 3: (following each raw material percentage composition is weight percentage)
Soyabean protein powder 70%
PURE WHEY 30%
Isoflavones 0.6%
FOS 4%
Calcium lactate 2%
Xanthans 0.7%
Lecithin 1%.
Preparation technology's step is with embodiment 1.
Zoopery result of the present invention is following:
Confirm that through zoopery product of the present invention can significantly prevent the generation of removal ovary osteoporosis rat, its experimental procedure and result are following:
1. animal origin and grouping
50 Healthy female SD rats of mating not, 3.5 monthly ages, body weight 250-280g, rat is divided into 5 groups by body weight at random after this laboratory adapted to for 1 week, 10 every group:
(1). false operative control group (Sham): sham-operation, promptly carry out the identical surgical procedure of oophorectomy, but do not extract ovary, only excise fritter fat, the feed protein source is casein;
(2). removal ovary control group (Ovx): removal ovary, the feed protein source is casein;
(3). do not strengthen isoflavones group (0-SI): removal ovary, the feed protein source is not for strengthening the common nutrition albumen powder of isoflavones;
(4). middle dosage isoflavones group (M-SI): removal ovary, the feed protein source is for strengthening the nutrition albumen powder of isoflavones, and its addition is the 350mg/100g albumen powder;
(5). high dose isoflavones group (H-SI): removal ovary, the feed protein source is for strengthening the nutrition albumen powder of isoflavones, and its addition is the 760mg/100g albumen powder.
Each treated animal basal feed is identical, and the feeding environment temperature is 20-24 ℃, humidity 40-60%, and illumination in 12 hours is alternately freely drunk water and is taken food.Operation back rat recovers 1 week to get into formal experimental period, observes the animal diet followed situation every day, weigh weekly once, and the consumption of per 3 days record feeds, the food ration of every day is respectively organized in clearing simultaneously.Raise after 3 months, rat is put to death in fasting 24 hours, gathers required sample and carries out functional evaluation.
2. testing index and method
Measure the rat femur bone density with double energy X-ray bone density (BMD) appearance; Utilize aas determination bone calcium; Bone phosphorus adopts peacock green-phosphomolybdic acid colorimetric method for determining; The colorimetric method for determining Serum alkaline phosphatase activity; Competitive serum measured by radioimmunoassay BGP content.
3. statistical procedures
All data are carried out analyzing and processing with the SPSS statistical software, and the result representes that with mean standard deviation x ± S representes, the significance of difference is with P＜0.05 and P＜0.01 expression.
4. nutrition albumen powder is to the influence of removal ovary rat body weight
Each organizes the rat ordinary circumstance and the postoperative wound healing is good, does not have and infects.Five groups of rat body weights all increase, at the 15th day 5 groups of mesosomes of experiment existing significant difference of reppearing, and removal ovary control group and do not strengthen isoflavones group body weight apparently higher than false surgical groups and isoflavones group, difference has statistical significance (P＜0.05, table 1); Continue to be higher than false surgical groups to testing end of term removal ovary control group and not strengthening isoflavones group body weight, difference has statistical significance (P＜0.01), compares body weight with false control group and does not significantly increase and strengthen various dose isoflavones group.The obesity that the nutrition albumen powder of strengthening isoflavones can prevent the removal ovary rat to cause owing to estrogen deficiency is described.
Table 1 nutrition albumen powder is to the influence of removal ovary rat body weight (x ± S)
Annotate: a compares P＜0.05 with false surgical groups, and b compares P＜0.01 with false sub-art group
5. nutrition albumen powder is to the influence of removal ovary rat bone density, bone calcium and bone phosphorus
Can find out from table 2; Compare removal ovary control rats bone density significantly descend (P＜0.01) with false surgical groups; Descend 12.9%, strengthen the albumen powder of various dose isoflavones after, bone density all be significantly increased (P＜0.05 and P＜0.01); Compare M-SI group with the removal ovary control group and you can well imagine high 5.9% and 12.1%, and do not strengthen the isoflavones group and compare that M-SI organizes and the H-SI component you can well imagine high 2.7% and 9.9% with the H-SI component.
Compare removal ovary control group bone calcium and bone phosphorus significantly descend (P＜0.01) with false surgical groups; Descend 3.8% and 12.7% respectively; Bone calcium and bone phosphorus all significantly improve (P＜0.01) behind the albumen powder of isoflavones and strengthen; Compare various dose isoflavones group bone calcium with the removal ovary control group and improve 4.2% and 4.8% respectively; Bone phosphorus improves 13.1% and 12.7% respectively, does not compare various dose isoflavones group calcium content of bone and improves 4.6% and 5.2% respectively with strengthening the isoflavones group, and the bone phosphorus content improves 11.5% and 11.8% respectively.
Table 2 nutrition albumen powder is to the influence of rat femur bone density and bone calcium, bone phosphorus (x ± S)
Annotate: a compares P＜0.01 with false surgical groups, and b compares P＜0.05 with the removal ovary control group, and c compares P＜0.01 with the removal ovary control group,
D does not compare P＜0.05 with strengthening the isoflavones group, e with do not strengthen the isoflavones group and compare P＜0.01
6. nutrition albumen powder is to the influence of removal ovary rat blood serum biochemical indicator
From table 3, can find out, compare the active significantly decline (P＜0.05) of removal ovary control rats serum AKP level with false surgical groups, descend 12.90%.After strengthening the albumen powder of various dose isoflavones, all be significantly increased (P＜0.01 and P＜0.05), compare M-SI group and H-SI component with the removal ovary control group and you can well imagine high 25.00% and 34.79%; The isoflavones group is compared the M-SI group and the H-SI component you can well imagine high 10.86% and 19.21% with not strengthening.
Compare removal ovary control group serum BGP content with false surgical groups and significantly raise (P＜0.05), raise 39.68%; Give that the rising of serum BGP content has obtained inhibition (P＜0.05) behind the isoflavones of dosage, compare with the removal ovary control group to have descended 25.77%, and do not strengthen the isoflavones group and compare and do not have significant difference; Give that the rising of serum BGP content has also obtained inhibition behind the isoflavones of high dose, but with the removal ovary control group with do not strengthen the isoflavones group and compare and do not have significant difference.
Table 3 nutrition albumen powder is to the influence of rat blood serum alkaline phosphatase and BGP (x ± S)
Annotate: a compares P＜0.05 with false surgical groups, and b compares P＜0.05 with ovariectomized group
C compares P＜0.01 with ovariectomized group, d with do not strengthen the isoflavones group and compare P＜0.05
The AKP unit definition: it is a King unit that 100ml serum produces 1mg phenol at 37 ℃ with matrix effect 15min.
7. conclusion:
This experiment was strengthened the albumen powder treatment ovariectomized group rat of isoflavones after 3 months; Rat femur bone density (BMD), bone calcium and bone phosphorus content significantly raise (p＜0.01); Show that isoflavones can reverse the bone loss that causes because of estrogen deficiency, play the osteoporotic effect of control.Bone alkaline phosphatase active (AKP) increase, BGP (BGP) content reduce in the serum, and the prompting Gegenbaur's cell is active to be increased, and the effect of prevention of osteoporosis is played in the decline of bone conversion rate.
Claims (3)
1. complex nutrition albumen powder that prevents women's osteosporosis after menopause, it is characterized in that: its constituent and percentage by weight thereof are respectively:
Described soyabean protein powder is a soybean protein isolate, its protein content >=60%;
Described PURE WHEY is a WPC, its protein content >=60%;
Total isoflavone content >=40% in the described isoflavones, and the content of isoflavones is to calculate with total isoflavone content;
Described compound sugar is soyabean oligosaccharides or oligoisomaltose or FOS or low poly lactose or galactooligosaccharide.
2. the complex nutrition albumen powder of prevention women's osteosporosis after menopause according to claim 1 is characterized in that: described stabilizing agent is xanthans or carragheen, or both mixtures.
3. the complex nutrition albumen powder of prevention women's osteosporosis after menopause according to claim 1 is characterized in that: described lecithin is the lecithin of homogeneous.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710150586XA CN101181069B (en) | 2007-11-30 | 2007-11-30 | Complex nutrition albumen powder for preventing women's osteosporosis after menopause |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710150586XA CN101181069B (en) | 2007-11-30 | 2007-11-30 | Complex nutrition albumen powder for preventing women's osteosporosis after menopause |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101181069A CN101181069A (en) | 2008-05-21 |
| CN101181069B true CN101181069B (en) | 2012-01-25 |
Family
ID=39446601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710150586XA Expired - Fee Related CN101181069B (en) | 2007-11-30 | 2007-11-30 | Complex nutrition albumen powder for preventing women's osteosporosis after menopause |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101181069B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2933617B1 (en) * | 2008-07-10 | 2010-09-17 | Alliospharma | COMPOSITIONS FOR PROMOTING THE DEVELOPMENT AND GROWTH OF A BENEFICIAL VAGINAL MICROFLORE |
| CN102599402B (en) * | 2011-01-25 | 2013-09-04 | 光明乳业股份有限公司 | Whey protein composition and preparation method thereof |
| CN103271166A (en) * | 2013-06-08 | 2013-09-04 | 山东省高唐蓝山集团总公司 | Soybean whey composite powder and preparation method thereof |
| CN104187244A (en) * | 2014-07-07 | 2014-12-10 | 山东省高唐蓝山集团总公司 | High-protein composition powder and preparation method thereof |
| CN104814445A (en) * | 2015-04-03 | 2015-08-05 | 梁德华 | Cardio-cerebrovascular disease preventing intensified protein powder and preparation method thereof |
| EP3284472B1 (en) * | 2015-04-07 | 2021-06-02 | Meiji Co., Ltd. | Hot flash-suppressing agent |
| CN105166937A (en) * | 2015-08-11 | 2015-12-23 | 曹峥峥 | Carya cathayensis protein powder |
| CN106666531A (en) * | 2016-12-28 | 2017-05-17 | 熙可食品(安徽)有限公司 | Cranberry can and preparation method thereof |
| CN110214955B (en) * | 2019-07-07 | 2024-02-02 | 广州正广生物科技有限公司 | Composition with function of nourishing ovaries and preparation method thereof |
| CN111357979A (en) * | 2019-12-26 | 2020-07-03 | 浙江欧谱生物科技有限公司 | Health food composition for inhibiting obesity and bone loss caused by high fat and application thereof |
| CN113080469A (en) * | 2021-04-13 | 2021-07-09 | 广州金酮医疗科技有限公司 | Preparation method of protein component |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1291442A (en) * | 2000-09-15 | 2001-04-18 | 卢挺 | Broad bean milk powder and its preparing process |
| CN100998368A (en) * | 2006-01-12 | 2007-07-18 | 天津科技大学 | Protein powder produced by fluidized bed spraying lecithinum granulation technique and preparing method thereof |
| CN101427784A (en) * | 2008-07-09 | 2009-05-13 | 内蒙古蒙牛乳业（集团）股份有限公司 | Liquid milk for pregnant and ylying-in woman with additive lecithin and method of producing the same |
-
2007
- 2007-11-30 CN CN200710150586XA patent/CN101181069B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1291442A (en) * | 2000-09-15 | 2001-04-18 | 卢挺 | Broad bean milk powder and its preparing process |
| CN100998368A (en) * | 2006-01-12 | 2007-07-18 | 天津科技大学 | Protein powder produced by fluidized bed spraying lecithinum granulation technique and preparing method thereof |
| CN101427784A (en) * | 2008-07-09 | 2009-05-13 | 内蒙古蒙牛乳业（集团）股份有限公司 | Liquid milk for pregnant and ylying-in woman with additive lecithin and method of producing the same |
Non-Patent Citations (2)
| Title |
|---|
| 张逢春等.大豆异黄酮抗骨质疏松症的实验研究及作用机制的探讨.《贵州医药》.2004,(第12期), * |
| 迟晓星等.大豆异黄酮对妇女更年期综合征及骨密度的作用研究.《中国骨质疏松杂志》.2005,(第03期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101181069A (en) | 2008-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101181069B (en) | Complex nutrition albumen powder for preventing women's osteosporosis after menopause | |
| CA2603518C (en) | Nutrient composition for promoting collagen production | |
| JP2012511547A (en) | Isoflavone composition | |
| CN106490605A (en) | A kind of hypertension of pregnancy tailored version clinical nutrition formula and preparation method thereof | |
| EP1652527A1 (en) | Accelerator for mineral absorption and use thereof | |
| CN113713084A (en) | Medicine and food dual purpose Chinese medicinal product for treating bone and joint pain and osteoporosis of middle aged and elderly people | |
| Bell et al. | Elderly women need dietary protein to maintain bone mass. | |
| CN102379415A (en) | Antioxidant healthcare capsule and preparation method thereof | |
| CN109276710A (en) | A kind of composition and its preparation method and application increasing bone density | |
| CN106036898A (en) | Composition having anti-fatigue effects and preparation method and use thereof | |
| JP3280420B2 (en) | Calcium absorption promoting composition containing soy milk | |
| Lee et al. | Supplementation of Korean fermented soy paste doenjang reduces visceral fat in overweight subjects with mutant uncoupling protein-1 allele | |
| JP2014152129A (en) | Bone formation accelerating agent, and foods and drinks, oral products and feeds for animals combined with bone formation accelerating agent | |
| KR20010103065A (en) | Diet composition comprising dietary fiber | |
| KR102262765B1 (en) | Composition for reinforcing bone density or treating osteoporosis comprising a ranch raw milk derived exosome | |
| KR20220118504A (en) | composition for suppressing obesity | |
| JP2000191526A (en) | Composition for stimulating formation of bone and preventing and treating bone osteoporosis | |
| TW200812569A (en) | Bone density increasing agent | |
| KR100921172B1 (en) | Compositions of slimming food containing dietary fiber for the treatment of obesity | |
| KR20040071349A (en) | Composition of functional food for prevention and treatment of osteoporosis | |
| WO2013174812A1 (en) | Fructus ligustri lucidi for bones in young subjects | |
| JP2004323469A (en) | Medicinal composition and food for prevention and treatment of type ii diabetes | |
| CN111528386B (en) | Hawthorn and natto solid beverage and preparation method thereof | |
| CN113712982B (en) | Composition for preventing or treating non-alcoholic fatty liver disease and obesity, and preparation method and application thereof | |
| KR101401002B1 (en) | Pharmaceutical composition and functional health food for prevention or treatment of diseases relating to bone mass loss including HS1792 or its pharmaceutically acceptable salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120125 Termination date: 20131130 |